B. Riley Securities Maintains Buy on TG Therapeutics, Raises Price Target to $34
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities has maintained a Buy rating on TG Therapeutics (NASDAQ:TGTX) and raised the price target from $29 to $34.
August 07, 2024 | 4:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B. Riley Securities has maintained a Buy rating on TG Therapeutics and raised the price target from $29 to $34.
The Buy rating and increased price target from a reputable analyst firm like B. Riley Securities is likely to positively impact investor sentiment and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100